cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in france.[2020][
本文档由 316072725c 分享于2020-03-12 19:27
cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in france.[2020][
下载文档
收藏
打印
分享：
君，已阅读到文档的结尾了呢~~